JADPRO Live Accredited Educational Activities

Earn continuing education (CE) credit with these accredited educational activities based on presentations from recent JADPRO Live at APSHO conferences. Access the full-length video presentation, the slide deck, transcript, and the entire lecture as a podcast. You can earn CE for each of these activities by following the links.

Click on any of the video presentations below to get started!

Multiple Myeloma  |  EGFR/NSCLC  |  irAEs  |  Breast Cancer  |  Urothelial Carcinoma  |  Colorectal Cancer  |  Ovarian Cancer  |  AML  |  CAR T-Cell Therapy  |  Drug Development  |  Soft Tissue Sarcomas  |  AML
Risk Stratification in Multiple Myeloma: Putting the Pieces Together

This activity is supported by unrestricted educational grants from Celgene Corporation and Takeda Oncology.

Multiple Myeloma

Risk Stratification in Multiple Myeloma: Putting the Pieces Together

While the past few years have shown an unprecedented increase in the number of agents available to treat patients with multiple myeloma, many advanced practitioners struggle with optimal agent choice, timing, and sequencing, especially related to the use of these newer agents in combination regimens. Learn about these aspects of treatment, as well as testing and diagnosis, risk stratification, emerging toxicities, and supporting patients on oral therapies.

Posted: January 22, 2018 / Expires: January 22, 2019

Credits/Contact Hours: 1.5

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This link will take you to the Annenberg
Center for Health Sciences website.


 
Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer

This activity is supported by independent educational grants from AstraZeneca, Pfizer, and Takeda Oncology.

EGFR/NSCLC

Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer

Learn about the recent updates in the world of genetic testing and targeted therapies for non–small cell lung cancer. It’s vital that advanced practitioners in oncology have the latest knowledge on EGFR, ALK, and BRAF inhibitors, as well as acquired resistance mutations, to help patients from diagnosis through treatment.

Posted: January 22, 2018 / Expires: January 22, 2019

Credits/Contact Hours: 1.0

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This link will take you to the Annenberg
Center for Health Sciences website.


 
Managing Side Effects of Cancer Patients Treated With Immunotherapy

This activity is supported by independent educational grants from AstraZeneca, Bristol-Myers Squibb, and Merck Sharp & Dohme Corp.

irAEs

Managing Side Effects of Cancer Patients Treated With Immunotherapy

Learn how to identify, assess, and manage the possible side effects from cancer immunotherapy, as well as how to educate patients on what to expect from treatment. With the constantly growing list of FDA-approved immunotherapies for cancer, it is vital that advanced practitioners in oncology remain up-to-date on this cutting-edge treatment area, including the questions that research has yet to answer.

Posted: January 22, 2018 / Expires: January 22, 2019

Credits/Contact Hours: 1.0

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This link will take you to the Annenberg
Center for Health Sciences website.


 
Advances in Extended Adjuvant HER2-Positive Early Breast Cancer

Supported by an educational grant from Puma Biotechnology.

Breast Cancer

Advances in Extended Adjuvant HER2-Positive Early Breast Cancer

Examine the mechanisms of action of extended adjuvant therapies for HER2-positive early breast cancer, in addition to strategies for combating patients’ side effects and the latest guidelines on HER2 testing. Advanced practitioners can also learn about their critical role in properly selecting patients for treatment, educating them about their treatment options, and managing treatment adherence.

Posted: January 22, 2018 / Expires: January 22, 2019

Credits/Contact Hours: 1.5

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This link will take you to the Annenberg
Center for Health Sciences website.


 
Advances in the Management of Patients with Urothelial Carcinomas of the Bladder

This activity is supported by an independent educational grant from Merck Sharp & Dohme Corp.

Urothelial Carcinoma

Advances in the Management of Patients with Urothelial Carcinomas of the Bladder

Get an update on the state of chemotherapy and immunotherapy for the treatment of urothelial carcinomas of the bladder. Learn how these therapies combat the various types of urothelial carcinomas and how to identify their most common side effects, including immune-related adverse effects from immunotherapy.

Posted: January 22, 2018 / Expires: January 22, 2019

Credits/Contact Hours: 1.0

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This link will take you to the Annenberg
Center for Health Sciences website.


 
Hereditary Aspects of Colorectal Cancer

This activity is supported by an independent educational grant from Merck Sharp & Dohme Corp.

Colorectal Cancer

Hereditary Aspects of Colorectal Cancer

Learn about Lynch syndrome and other hereditary colorectal cancer syndromes, in addition to which patients are at risk, how to screen for these syndromes, and the relationship between biomarkers and targeted therapies for colorectal cancer. With 95% of Americans with Lynch syndrome unaware of their condition, it is vital that advanced practitioners in oncology be well-versed in the hereditary aspects of colorectal cancer to ensure patients are diagnosed effectively and receive the appropriate treatment.

Posted: January 22, 2018 / Expires: January 22, 2019

Credits/Contact Hours: 1.0

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This link will take you to the Annenberg
Center for Health Sciences website.


 
New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents

This activity is supported by independent educational grants from AstraZeneca, Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, Puma Biotechnology, Takeda Oncology, and TESARO, Inc.

Ovarian Cancer

New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents

Get updated on the latest drug treatments for solid tumors and the clinical trial data behind their FDA approvals. And importantly, learn how to spot the common adverse side effects from these newly approved treatments and how to help patients manage them.

Posted: January 22, 2018 / Expires: January 22, 2019

Credits/Contact Hours: 1.0

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This link will take you to the Annenberg
Center for Health Sciences website.


 
A Deeper Dive into Advanced and Future Directions in Treating Patients with Acute Myeloid Leukemia

Supported by unrestricted educational grants from Astellas Pharma Global Development, Inc. and Jazz Pharmaceuticals.

AML

A Deeper Dive into Advanced and Future Directions in Treating Patients with Acute Myeloid Leukemia

Hear from expert advanced practitioners about the updated WHO classification criteria and today’s leading-edge treatments for AML. Also learn about the molecular mutations commonly associated with this disease and how to identify patients who are genetically predisposed.

Posted: January 22, 2018 / Expires: January 22, 2019

Credits/Contact Hours: 1.5

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This link will take you to the Annenberg
Center for Health Sciences website.


 
New Drug Updates in Hematologic Malignancies: CAR T Cells, Targeted Therapeutics, and Other Agents

This activity is supported by independent educational grants from Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, Puma Biotechnology, Takeda Oncology.

CAR T-Cell Therapy

New Drug Updates in Hematologic Malignancies: CAR T Cells, Targeted Therapeutics, and Other Agents

Get an update on the fast-changing world of therapies for hematologic malignancies. With the constantly growing list of new drugs and indications, as well as the introduction of cutting-edge CAR T-cell therapy for the treatment of hematologic malignancies, it’s important that advanced practitioners stay up to date on the latest advances to be able to adequately diagnose, treat, and help patients navigate potential side effects.

Posted: January 22, 2018 / Expires: January 22, 2019

Credits/Contact Hours: 1.0

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This link will take you to the Annenberg
Center for Health Sciences website.


 
Drug Development

An Address From Dr. Richard Pazdur: How the Changing Landscape of Oncology Drug Development and Approval Will Affect Advanced Practice

Get an inside perspective on how the FDA updates its drug approval processes to reflect the changing oncology treatment environment and to incorporate the voice of the patient. With increasing numbers of oncology drug approvals and the ever-important area of molecularly targeted therapy, it is critical that advanced practitioners embrace and support this change.

Posted: January 22, 2018 / Expires: January 22, 2019

Credits/Contact Hours: 1.0

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This link will take you to the Annenberg
Center for Health Sciences website.


 
Optimizing Outcomes for Patients With Soft-Tissue Sarcomas Through the Multidisciplinary Medical Oncology/Radiation/Surgical Team Approach

This activity is supported by an independent educational grant from Lilly USA, LLC.

Soft Tissue Sarcomas

Optimizing Outcomes for Patients With Soft-Tissue Sarcomas Through the Multidisciplinary Medical Oncology/Radiation/Surgical Team Approach

Discover how to cultivate and personalize a multidisciplinary approach—involving the medical oncology, radiation, and surgical teams—to treating patients with soft tissue sarcoma in your own institution. In addition, get an update on the staging criteria and current state of systemic, surgical, and radiation therapy options for this disease. 

Posted: January 22, 2018 / Expires: January 22, 2019

Credits/Contact Hours: 1.0

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This link will take you to the Annenberg
Center for Health Sciences website.


 
Managing the Continuum of Myeloid Malignancies (CML, MPN, MDS, and AML)

This activity is supported by independent educational grants from Astellas Pharma Global Development, Inc., Celgene Corporation, and Jazz Pharmaceuticals.

AML

Managing the Continuum of Myeloid Malignancies (CML, MPN, MDS, and AML)

Take a deep dive into the updated WHO criteria for diagnosing myeloid malignancies, the mechanisms of action of new novel therapies, and the growing role of molecular mutations, while also learning how to take a collaborative, multidisciplinary approach to classifying these diseases. Advanced practitioners are key to managing the evolving continuum of myeloid malignancies and creating a multidisciplinary team approach to managing patients with complex myeloid malignancies.

Posted: January 22, 2018 / Expires: January 22, 2019

Credits/Contact Hours: 1.0

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This link will take you to the Annenberg
Center for Health Sciences website.


 
Head and Neck  |  Immunotherapy  |  MULTIPLE MYELOMA  |  Aggressive Lymphomas  |  Gastric Cancer  |  VTE  |  CINV  |  Pancreatic  |  CLL  |  Infectious Complications  |  CAR-T  |  Skin  |  Breast  |  Lung
Advances in Collaborative Practice for Patients with Head and Neck Cancers

This activity is supported by an educational grant from Bristol-Myers Squibb.

Head and Neck

Advances in Collaborative Practice for Patients with Head and Neck Cancers

Head and neck cancer care is complex, and there are limited treatment options; over the past decade only one new therapy received FDA approval. However, as in other tumor types, the landscape is changing with the recent emergence of newer targeted therapies and immunotherapies. This learning activity will provide advanced practitioners with valuable updates on screening and prevention, the risk associated with human papillomavirus (HPV), treatment options, mechanisms of action for new therapies, and monitoring for and the management of adverse events.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 1.0

Watch Video Without Claiming Credit

 
Immunotherapy Advances and Updates

This activity is supported by an educational grant from Merck & Co.

Immunotherapy

Immunotherapy: Advances and Updates

One of the greatest advances in oncology over the past decade has been the recognition of cell surface proteins that are shown to play a key role in tumor immunogenicity; mechanisms in which tumors are able to avoid immune surveillance and destruction. Although immunotherapy is a relatively new approach to anti-cancer treatment, it is being utilized across multiple tumor types. This program highlights the science behind immunotherapy, immune-related adverse side effects (irAEs), monitoring and managing irAEs, the role of biomarkers, and differentiating pseudo-progression from actual disease progression.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 1.0

Watch Video Without Claiming Credit

 
New Drugs and Novel Mechanisms of Action in Treating Patients with Multiple Myeloma

This activity is supported by an educational grant from Celgene and Takeda Oncology.

MULTIPLE MYELOMA

New Drugs and Novel Mechanisms of Action in Treating Patients with Multiple Myeloma

Despite the fact that multiple myeloma remains incurable, mean overall survival has improved dramatically as newer game-changing therapies enter the scene. At the same time, treatment decisions are becoming more complex. This educational activity provides indispensable information regarding risk categories, mechanisms of action for newer drugs, appropriate therapeutic options and sequencing, including identification of transplant eligible patients, and the management of toxicities related to newer drug regimens, thus equipping advanced practitioners to provide optimum clinical support for their patients throughout the trajectory of their disease. 

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 1.0

Watch Video Without Claiming Credit

 
Nuances in the Management of Aggressive Lymphomas

This activity is supported by an educational grant from Genentech.

Aggressive Lymphomas

Nuances in the Management of Aggressive Lymphomas

Treatment for both Hodgkin and non-Hodgkin’s lymphoma now includes chemotherapy, targeted therapy, and new immunotherapies. As research continues to shine the light on tumor genetics, clinical variability, and new treatment approaches, advanced practitioners (APs) need to translate this information to the bedside in the management of aggressive lymphomas. This educational activity will provide APs with the latest update on emerging treatments for aggressive, relapsed/refractory lymphomas, as well as potential adverse events and how to manage them, with the goal of optimizing treatment effectiveness and patient outcomes.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 1.0

Watch Video Without Claiming Credit

 
Collaborative Management of Patients with Gastric Cancer

This activity is supported by an unrestricted educational grant from Bristol-Myers Squibb, Lilly USA, LLC, and Merck & Co.

Gastric Cancer

Collaborative Management of Patients with Gastric Cancer

Advanced gastric and esophageal cancers are associated with poor outcomes. However, as knowledge of disease biology improves, treatment options are increasing. Genomic profiling has identified targetable mutations or biomarkers, such as HER2. Immunotherapies such as checkpoint inhibitors may be approved for gastrointestinal malignancies in the very near future. This program provides an overview of clinical trials, new treatment options, as well as practical clinical information regarding diagnosis, staging, monitoring, and managing side effects to treatment, in order to ameliorate clinical confidence and patient outcomes.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 1.0

Watch Video Without Claiming Credit

 
Management of Venous Thromboembolism for Patients with Hematologic Malignancies

This activity is supported by an educational grant from Celgene.

VTE

Management of Venous Thromboembolism for Patients with Hematologic Malignancies

Advanced practitioners (APs) are an integral part of the cancer care team. Therefore, it is imperative they are knowledgeable of risk factors associated with venous thromboembolism (VTE) in the oncology setting, including signs or symptoms and management. Early intervention is crucial. APs must also be able to differentiate between anticoagulation drugs and select the appropriate treatment for their patient with VTE. This educational program will provide the AP with an overview of VTE risks in cancer patients, indications and contraindications for prophylaxis or treatment, antidotes/reversal agents, and patient monitoring.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 0.75

Watch Video Without Claiming Credit

 
Management of Patients with Chemotherapy Induced Nausea and Vomiting

This activity is supported by an educational grant from Genentech.

CINV

Management of Patients with Chemotherapy - Induced Nausea and Vomiting

The first 5-HT3 antagonist was approved in 1991 for the management of chemotherapy-induced nausea and vomiting (CINV), leading to moving more chemotherapy regimens to the outpatient setting and improving adherence to treatment. Since then, several 5-HT3 antagonists and NK-1 receptor antagonists have been added to the armamentarium. Despite advances, CINV is often inadequately prevented and/or managed. This learning activity reviews current evidence-based interventions for the prevention and management of CINV, including physiologic mechanisms associated with CINV, strategies to target the pathways involved in CINV, and recommended guidelines.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 0.75

Watch Video Without Claiming Credit

 
What Advanced Practitioners Need to Know About the Diagnosis and Treatment of Patients With Pancreatic Cancer

This activity is supported by an educational grant from Celgene and Merrimack Pharmaceuticals, Inc.

Pancreatic

What Advanced Practitioners Need to Know About the Diagnosis and Treatment of Patients With Pancreatic Cancer

Pancreatic cancer is known to carry a poor prognosis. Only 15%–20% of patients present with potentially resectable disease, and therefore accurate diagnosis and staging is essential. It is also important that providers are aware of emerging data and guidelines regarding second- and third-line treatment options. This educational activity will provide the advanced practitioner with important information regarding risk assessment, diagnostic workup, treatment considerations (including surgery, radiation, and chemotherapy), and supportive care.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 1.0

Watch Video Without Claiming Credit

 
Defining the New Treatment Paradigm for Patients with Chronic Lymphocytic Leukemia

This activity is supported by an educational grant from AbbVie, Celgene, Genentech, and Gilead.

CLL

Defining the New Treatment Paradigm for Patients with Chronic Lymphocytic Leukemia

Oncology care is undergoing dynamic changes across tumor types with novel therapies being developed at a rapid pace. Within the past 3 years, the FDA has approved five new treatment options for patients with CLL. While these advances improve patient outcomes and the quality of care, the need for advanced practitioners (APs) to stay up to date and informed in order to translate these advances into the clinical setting is daunting. This educational activity will provide APs with important information on the diagnostic workup, risk assessment/prognostic indicators, optimizing treatment selection, response monitoring, mechanism of actions, and side effect management of newer therapies.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 1.0

Watch Video Without Claiming Credit

 
Best Practices in the Management of Infectious Complications for Patients with Cancer

This activity is supported by an independent medical educational grant from Sandoz Inc., a Novartis Company.

Infectious Complications

Best Practices in the Management of Infectious Complications for Patients with Cancer

Immune suppression increases the risk for developing infection and/or sepsis. As antibiotic resistant bacteria are becoming ubiquitous, managing infection becomes more complex. Optimizing preventive measures, early diagnosis and management of infection is of the highest priority in cancer care. This educational activity will enable advanced practitioners to hone their skills in risk assessment, recognition and early intervention in the management of infection, optimizing treatment in the era of antibiotic-resistant bacteria, and understand the role of biosimilars and their reference G-CSFs in the prophylaxis and treatment of febrile neutropenia.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 0.75

Watch Video Without Claiming Credit

 
Understanding the Mechanism of Action for Chimeric Antigen Receptor Therapy

This activity is supported by an educational grant from Genentech.

CAR-T

Understanding the Mechanism of Action for Chimeric Antigen Receptor (CAR) Therapy

Adoptive immunotherapy involves engineering the patient’s own T-cells by artificially equipping them with chimeric antigen receptors (CARs) which then enable them to bind to certain proteins on the surface of malignant cells. Referred to as CAR-T cell therapy, this form of treatment has had stunning results in acute lymphoblastic leukemia (ALL) and lymphoma. Cytokine release syndrome (CRS), which can be severe and involve multi-organ failure, is a major potential toxicity. This program will provide advanced practitioners with cutting edge information about adoptive CAR-T cell immunotherapy, mechanism of action, unique and potentially serious side effects, and how to monitor for and manage CRS.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 1.0

Watch Video Without Claiming Credit

 
Management of Patients with Skin Cancers Basal Cell Carcinoma and Melanoma

This activity is supported by an educational grant from Bristol-Myers Squibb and Merck & Co, Inc.

Skin

Management of Patients with Skin Cancers: Basal Cell Carcinoma and Melanoma

Novel, cutting-edge therapies are changing the treatment paradigm for both melanoma and advanced/metastatic basal cell carcinoma. While immunotherapies are increasing survival benefits in melanoma, they are associated with unique, potentially severe or even lethal immune-related adverse events (irAEs). Many advanced practitioners lack familiarity with newer immunotherapies and hedgehog inhibitors. This learning activity will equip APs with the knowledge needed to provide safe, state-of-the-art care for their patients with melanoma or basal cell skin cancer.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 0.75

Watch Video Without Claiming Credit

 
Collaborative Management of Patients with Advanced Estrogen Receptor-Positive Breast Cancer

This activity is supported by an educational grant from Lilly and Merck.

Breast

Collaborative Management of Patients with Advanced Estrogen Receptor-Positive Breast Cancer

The standard treatment approach for ER+ breast cancer includes surgery, radiation, or both, along with chemotherapy, endocrine therapy, targeted therapy, or combinations of these approaches. Cyclin-dependent kinase (CDK) inhibitors represent a new form of cytotoxic chemotherapy. The major side effect is hematologic toxicity, however, this differs from the hematologic effects associated with conventional cytotoxic chemotherapy. This educational program will provide advanced practitioners valuable insight into the science behind CDK inhibition, when CDKs are indicated, how to monitor for and manage side effects, as well as when and how to dose adjust.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 1.0

Watch Video Without Claiming Credit

 
Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinoma of the Lung

This activity is supported by an educational grant from AstraZeneca, Bristol-Myers Squibb, Celgene, Lilly, and Merck.

Lung

Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinoma of the Lung

Following years in which there were only modest gains in treatment options for non–small cell lung cancer, the number of drugs approved in the past 5 years is unprecedented. Recognition of targetable mutations and immunogenicity of lung cancer now impact treatment decisions. This educational activity will provide the advanced practitioner with updates on the latest research, current guidelines in the diagnosis and workup, as well as information on novel treatments and side effect management to ensure the best outcomes for patients with NSCLC.

Posted: January 17, 2017 / Expires: January 17, 2018

Credits/Contact Hours: 1.0

Watch Video Without Claiming Credit

 
Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.